



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

Facile Alternative Synthesis of 1-Alkyl-5-alkylamino-6-phenethyluracils

Zhili Zhang ^a, Zhijian Cheng ^b, Xiaoyan Ma ^a,
Xiaowei Wang ^a & Junyi Liu ^{a c}

^a Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, China

^b Department of Chemistry, College of Jiujiang, Jiujiang, China

^c State Key Laboratory of Natural and Biomimetic Drug, Peking University, Beijing, China

Version of record first published: 01 Jun 2009.

To cite this article: Zhili Zhang , Zhijian Cheng , Xiaoyan Ma , Xiaowei Wang & Junyi Liu (2009): Facile Alternative Synthesis of 1-Alkyl-5-alkylamino-6-phenethyluracils, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 39:13, 2310-2316

To link to this article: <http://dx.doi.org/10.1080/00397910802654765>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Facile Alternative Synthesis of 1-Alkyl-5-alkylamino-6-phenethyluracils

Zhili Zhang,¹ Zhijian Cheng,² Xiaoyan Ma,¹ Xiaowei Wang,¹
and Junyi Liu^{1,3}

¹Department of Chemical Biology, School of Pharmaceutical Sciences,
Peking University, Beijing, China

²Department of Chemistry, College of Jiujiang, Jiujiang, China

³State Key Laboratory of Natural and Biomimetic Drug,
Peking University, Beijing, China

Abstract: A short alternative synthesis of 1-alkyl-5-alkylamino-6-phenethyluracil is described in 47% overall yield of **1a** via five steps starting from commercially available 6-methyluracil.

Keywords: 1,5-Disubstituted-6-phenethyluracil, heterocycles, synthesis

Pyrimidine and its derivatives are important classes of biologically active heterocyclic compounds. Various 5-alkyl substituted derivatives of uracil have been synthesized for both anticancer and antiviral properties. Notable among them is 6-benzyl-1-(benzyloxymethyl)-5-isopropyluracil (TNK651) (Fig. 1), which is one of the most potent agents effective against HIV-1 reverse transcriptase (HIV-1 RT).^[1] Currently, research work in our laboratory has concerned access to 1,5-dialkylsubstituted-6-phenethyluracils I and II (Fig. 1) and their derivatives as potent nonnucleoside HIV-1 RT inhibitors.^[2,3] In a previous publication, we described the preparation of 1-alkyl-5-dimethylamino-6-phenethyluracil^[2] from 6-methyluracil via six-stage reactions in 34% total yield.

Received August 25, 2008.

Address correspondence to Junyi Liu, Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China. E-mail: lilybmu@bjmu.edu.cn





Figure 1. Structures of TNK651, I and II.

However, the both procedures involve six synthetic steps^[2] from 6-methyluracil as the starting material and limit a number of other N⁵-substituted reactions. Herein, a shorter (five-step), facile, alternative synthesis of the title compounds (Scheme 1) is reported. The total yield of **1a** was 47%, which represents a big improvement in overall yield.

First, we investigated the halogenations of 6-methyluracil (**2**). Initial attempts to get access to the compounds **3** using ICl-MeOH^[4,5] failed or led to poor yields. However, treatment of **2** with PbO₂-HOAc-I₂^[6] at



Scheme 1. Reagents and conditions: (a) PbO₂, HOAc, I₂, 50°C, 3 h; (b) ClCH₂OCH₂CH₃, BSA, CH₃CN, rt; (c) PhCH₂Br, NaH, DMF; (d) (CH₃)₂NH or CH₃NH₂; and (e) HCOONH₄, Pd/C, MeOH.

50°C provided the 5-iodo-6-methyluracil **3** in 94% yield after purification by column chromatography. Compound **3** was transformed into 1-ethoxymethyluracil (**4**) via reaction with N,O-bis(trimethylsilyl)acetamide (BSA) and chloromethylethyl ether in CH₃CN. Treatment of **3** or **4** with benzyl bromide and NaH in tetrahydrofuran (THF) gave 1,3-dibenzyl-5-iodo-6-phenethyluracil (**5b**) in 82–85% yield and 1-ethoxymethyl-3-benzyl-5-iodo-6-phenethyluracil (**5a**) in 87% yield. Compound **5a** was transformed into 1-ethoxymethyl-3-benzyl-5-(*N,N*-dimethylamino)-6-phenethyluracil (**6a**) via replacement of iodo by dimethylamine under reflux. Compound **5b** was transformed into 1,3-dibenzyl-5-(*N,N*-dimethylamino)-6-phenethyluracil (**6b**) and 1,3-dibenzyl-5-(*N*-methylamino)-6-phenethyluracil (**6c**) with the reaction of dimethylamine or methylamine, respectively. Compounds **6a**, **6b**, and **6c** can be smoothly deprotected into title compounds **1a**, **1b**, and **1c** in 53–87% yield using HCOONH₄-Pd/C in MeOH under reflux.

All the compounds were characterized by ¹H NMR, mass, and infrared (IR) spectral data, and the final compound **1b** was additionally characterized by ¹³C NMR.

In conclusion, we have developed a convenient method to synthesize N⁵-substituted-6-phenethyluracil. This route is a shorter sequence than the previously published procedure for the compounds **1a**, **1b**, and **1c** and their derivatives, and will have broad application when these kinds of N⁵-substituted pyrimidine compounds are explored for therapeutic utilities.

EXPERIMENTAL

Melting points (uncorrected) were determined with an X₄-type apparatus. ¹H and ¹³C NMR spectra were recorded on a JNM-AL-300 or a Varian Inova-500 spectrometer using tetramethylsilane (TMS) as an internal standard. Mass spectra (MS) were recorded on a VG-ZAB-HS spectrometer. IR spectra were recorded with Avatar 360 Fourier transform (FT)-IR and are reported in centimeters⁻¹. Silica gel (0.40–0.64 mm) was used for column chromatography.

5-Iodo-6-methyl uracil (**3**)

PbO₂ (66 mg, 0.28 mmol) was added in portions to the suspension of 6-methyluracil (63 mg, 0.5 mmol) in glacial HOAc (15 mL) while stirring, and then I₂ (70 mg, 0.28 mmol) was added. The reaction mixture was heated to 50°C for 3 h. The PbO₂ was filtered, and then the filtrate was diluted with H₂O (80 mL). The precipitate was isolated, washed with

water and ether, then dried in vacuo to give a solid (118 mg, 94%), mp > 300°C. ¹H NMR (300 MHz, DMSO-d₆): δ = 11.40 (s, 1H, NH), 11.54 (s, 1H, NH), 2.64 (s, 3H, CH₃). EIMS: *m/z* = 257 [*M* + 1]⁺.

1-Ethoxymethyl-5-iodo-6-methyluracil (4)

BSA (0.37 mL, 1.24 mmol) was added to the solution of 5-iodo-6-methyluracil **3** (120 mg, 0.47 mmol) in CH₃CN (15 mL). The solution was stirred at rt for 50 min, then the ClCH₂OCH₂CH₃ (45 μL, 0.48 mmol) and LiI (50 mg) were added. The resulting mixture was stirred at rt for 75 min and quenched by addition of NaHCO₃. The solution was extracted with EtOAc (3 × 15 mL), and the combined extracts were washed with H₂O and dried over MgSO₄. The solvent was removed to give the crude product, which was purified by column chromatograph (EtOAc/petrol. 1:1) to yield the product (110 mg, 73%), mp 163°C (dec). ¹H NMR (300 MHz, CDCl₃): δ = 8.30 (s, 1H, NH), 5.24 (s, 2H, CH₂), 3.65 (q, *J* = 7.2 Hz, CH₂), 2.51 (s, 3H, CH₃), 1.22 (t, *J* = 7.0 Hz, 3H, CH₃). EIMS: *m/z* = 314 [*M*⁺].

1-Ethoxymethyl-3-benzyl-5-iodo-6-phenethyluracil (5a)

NaH (27 mg, 0.64 mmol, 60% in oil) was added to a solution of 1-ethoxymethyl-5-iodo-6-methyluracil **4** (100 mg, 0.32 mmol) in DMF (10 mL), portionwise under N₂. The mixture was stirred at rt for 1 h, and benzylbromide (1.16 mL, 0.8 mmol) was slowly added. The resulting mixture was stirred for 2–2.5 h, and water (20 mL) was added. After it was concentrated to dryness, the residue was dissolved in CH₂Cl₂ (20 mL) and washed with water. The aqueous layer was extracted with CH₂Cl₂. The combined organic layer was washed with brine, dried over Na₂SO₄, and evaporated to give the crude product, which was chromatographed (EtOAc–petrol. 1:2) to give 137 mg (87%) of **5a**, mp 173–175°C. ¹H NMR (300 MHz, CDCl₃): δ = 1.23 (t, *J* = 7.0 Hz, 3H, CH₃), 2.93–3.04 (m, 4H, CH₂CH₂), 3.63 (q, *J* = 7.0 Hz, 2H, CH₂), 5.32 (s, 2H, CH₂Ph), 5.45 (s, 2H, CH₂O), 7.18–7.25 (m, 10H, 2Ar). EIMS: *m/z* = 491 [*M* + 1]⁺.

1,3-Dibenzyl-5-iodo-6-phenethyluracil (5b)

NaH (110 mg, 2.73 mmol, 60% in oil) was added to the solution of 5-iodo-6-methyluracil **3** (200 mg, 0.78 mmol) in dimethylformamide (DMF) under N₂. The reaction mixture was stirred at rt for 1 h, and then benzylbromide (3.6 mL, 2.57 mmol) was added. After reaction for 2 h at rt, the

mixture was poured into H₂O (25 mL) and extracted with EtOAc. The combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated to give the residue, which was purified by chromatography on silica gel (EtOAc–petrol. = 1:3) to give the solid **5b** (340 mg, 82%), mp 114°C (dec). ¹H NMR (300 MHz, CDCl₃): δ = 2.81–2.93 (m, 4H, CH₂CH₂), 5.16 (s, 2H, CH₂Ph), 5.19 (s, 2H, CH₂Ph), 7.14–7.62 (m, 15H, 3Ph). EIMS: *m/z* = 523 [M + 1]⁺.

1-Ethoxymethyl-3-benzyl-5-(*N,N*-dimethylamino)-6-phenethyluracil (**6a**)

The excess (CH₃)₂NH (4 mL) was added to the solution of compound **5a** (500 mg, 1.02 mmol) in THF (1 mL). Then the solution was heated to 60°C for 30–35 h. After the reaction mixture was cooled to rt, H₂O (10 mL) was added and extracted with EtOAc (3 × 15 mL). The organic layer was washed with H₂O and dried over Na₂SO₄. The solvent was removed to give the product (oil) (380 mg, 90%) after purification by column chromatography (petrol.–EtOAc = 9:1). IR (KBr): 2935, 1705, 1655, 1447, 1095, 702 cm^{−1}. ¹H NMR (300 MHz, CDCl₃): δ = 1.23 (t, *J* = 6.9 Hz, 3H, CH₃), 2.71 (s, 6H, (CH₃)₂N), 2.80–2.89 (m, 4H, CH₂CH₂), 3.64 (q, *J* = 6.9 Hz, 2H, CH₂), 5.12 (s, 2H, CH₂), 5.30 (s, 2H, CH₂), 7.23–7.45 (m, 10H, 2Ar). ESI-TOF: *m/z* = 408.52 [M + 1]⁺, 430.53 [M + Na]⁺.

1,3-Dibenzyl-5-(*N,N*-dimethylamino)-6-phenethyluracil (**6b**)

The general procedure was similar to **6a**. Yield 340 mg (80%), mp 139–141°C.^[2] ¹H NMR (300 MHz, CDCl₃): δ = 2.71 (s, 6H, N(CH₃)₂), 2.79–3.01 (m, 4H, CH₂CH₂), 5.12 (s, 2H, NCH₂Ph), 5.17 (s, 2H, NCH₂Ph), 7.19–7.54 (m, 15H, 3Ar). EIMS: *m/z* = 439 [M⁺].

1,3-Dibenzyl-5-(*N*-methylamino)-6-phenethyluracil (**6c**)

The procedure was similar to **6a**. Yield 310 mg (76%), mp 146°C (dec). ¹H NMR (300 MHz, CDCl₃): δ = 2.63 (s, 3H, CH₃), 2.74–2.97 (m, 4H, CH₂CH₂Ph), 5.01 (s, 2H, CH₂Ph), 5.29 (s, 2H, CH₂Ph), 7.06–7.60 (m, 15H, 3Ar). EIMS: *m/z* = 425 [M⁺].

1-Ethoxymethyl-5-(*N,N*-dimethylamino)-6-phenethyluracil (**1a**)

HCO₂NH₄ (200 mg, 3.20 mmol) and 10% Pd/C (160 mg) were added to the solution of compound **6a** (55 mg, 0.11 mmol) in ethanol (12 mL).

The reaction mixture was heated under reflux for 7–7.5 h, then cooled to rt, filtered, and concentrated under reduced pressure to give **7a**, which was purified by column chromatography (CHCl_3 –MeOH = 95:5) to give 31 mg (87%), mp 142–143°C.^[2] IR (KBr): 3024, 1709, 1665, 1460, 1082 cm^{-1} . ^1H NMR (300 MHz, CDCl_3): δ = 1.24 (t, J = 6.9 Hz, 3H, CH_3), 2.67 (s, 6H, $\text{N}(\text{CH}_3)_2$), 2.88–3.16 (m, 4H, CH_2CH_2), 3.62 (q, J = 6.9 Hz, 2H, CH_2), 5.21 (s, 2H, CH_2O), 7.19–7.31 (m, 5H, Ph), 8.60 (s, H, $\text{N}_3\text{-H}$). ESI-TOF: m/z = 318.32 $[\text{M} + 1]^+$, 340.35 $[\text{M} + \text{Na}]^+$.

1-Benzyl-5-(*N,N*-dimethylamino)-6-phenethyluracil (**1b**)

Pd/C (300 mg) and HCOONH_4 (270 mg, 4.1 mmol) were added to the solution of compound **6b** (100 mg, 0.22 mmol) in dry MeOH. The mixture was refluxed for 3 days and then cooled to rt. The catalyst was filtered through a celite pad, washed with CHCl_3 , and concentrated under reduced pressure to give solid **1b**, which was purified by silica column chromatography (CHCl_3 –MeOH = 9:1). Yield 43 mg (53%), mp 147–148°C.^[2] ^1H NMR (300 MHz, CDCl_3): δ = 2.64 (s, 6H, CH_3), 2.80–2.94 (m, 4H, CH_2CH_2), 5.10 (s, 2H, CH_2Ph), 7.21–7.46 (m, 10H, 2Ph), 10.42 (s, 1H, NH). ^{13}C NMR (75 MHz, CDCl_3): 31, 33.9, 43.1, 43.5, 124, 126.7, 127.3, 128.2, 128.7, 137.2, 140.7, 150.7, 153.1, 161.8. EIMS: m/z = 349 $[\text{M}]^+$.

1-Benzyl-5-(*N*-methylamino)-6-phenethyluracil (**1c**)

The general procedure was similar to **1b**. ^1H NMR (300 MHz, CDCl_3): δ = 2.59 (s, 3H, CH_3), 2.81–2.95 (m, 4H, $\text{CH}_2\text{CH}_2\text{Ph}$), 3.26 (s, 1H, NH), 5.12 (s, 2H, CH_2Ph), 7.51–7.27 (m, 10H, 2Ar), 9.27 (s, 1H, N_3H). EIMS: m/z = 336 $[\text{M} + 1]^+$.

ACKNOWLEDGMENTS

We thank the National Sciences Foundation of China (No. 20672008) and 985 Program of the Ministry of Education of China for financial support.

REFERENCES

1. Xiaowei, W.; Qinghua, L.; Ying, G.; Yang, X.; Zhili, Z.; Junyi, L. The design and synthesis of 9-phenylcyclohepta[d]pyrimidine-2,4-dione derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. *Org. Biomol. Chem.* **2006**, *4*, 3252–3258.

2. Xiaowei, W.; Yanli, C.; Ying, G.; Amin, L.; Xiaoyan, M.; Junyi, L. Synthesis of 1-(alkyl)-5-dimethylamino-6-phenethyluracils as potent non-nucleoside HIV-1 RT inhibitors synthetic communications. *Synth. Commun.* **2007**, *37*, 2421–2431.
3. Xiao, L.; Yanli, C.; Ying, G.; Zhenming, L.; Yawei, S.; Yang, X.; Xiaowei, W.; Zhili, Z.; Junyi, L. The design and synthesis of N-1-alkylated-5-aminoaryalkyl-substituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors. *Bioorg. Med. Chem.* **2007**, *15*, 7399–7407.
4. Das, B.; Kundu, N. G. An efficient method for the iodination of C₅-position of dialkoxy pyrimidines and uracil bases. *Synth. Commun.* **1988**, *18*, 855–867.
5. Jacob, L. A.; Chen, B. L.; Stec, D. Further studies on the iodination of aryltrimethylsilanes. *Synthesis* **1993**, *6*, 611–614.
6. Barbara, K. S.; Piotr, L.; Lech, S. Aromatic iodination of activated arenes and heterocycles with lead tetraacetate as the oxidant. *Synthesis* **1995**, 926–928.